Back to discover
Drug

Ifenprodil

In clinical development
Emerging researchEarly-to-mid development

Also known as Ifenprodilum.

RxNorm27403ChEMBLCHEMBL305187ATCC04AX28UNIIR8OE3P6O5S
2
Research papers
1
Active clinical trials
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Phase 2 Trial Assessing Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis

Clinical trial2024-03-26Results expected Q1 2027 · ClinicalTrials.gov

An Open Label Study of the Efficacy, Safety and Tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and Its Associated Cough

Clinical trial2022-05-10Completed · ClinicalTrials.gov

Soluble Aβ oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors.

Research2011-05-01The Journal of neuroscience : the official journal of the Society for Neuroscience

Differential roles of NR2A and NR2B-containing NMDA receptors in cortical long-term potentiation and long-term depression.

Research2004-09-01The Journal of neuroscience : the official journal of the Society for Neuroscience

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Ifenprodil
Aliases & brands
Ifenprodilum
RxNorm CUI
27403
ChEMBL ID
CHEMBL305187
ATC codes
C04AX28
UNII
R8OE3P6O5S

Clinical trials

2 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
2
registered trials across all phases
LATEST COMPLETION 2022
1
Active studies
1
Recruiting
1
Completed
PHASE DISTRIBUTIONn = 2
Phase 22

Recent completions

Trials that read out recently, adding to the completed evidence base.

An Open Label Study of the Efficacy, Safety and Tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and Its Associated Cough

CompletedPH IIAlgernon Pharmaceuticalsn=202022

Research activity

2 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20042011
Most influential

Differential roles of NR2A and NR2B-containing NMDA receptors in cortical long-term potentiation and long-term depression.

The Journal of neuroscience : the official journal of the Society for Neuroscience · 2004 · 539 cites

Soluble Aβ oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors.

The Journal of neuroscience : the official journal of the Society for Neuroscience · 2011 · 533 cites
Recent papers

Soluble Aβ oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors.

The Journal of neuroscience : the official journal of the Society for Neuroscience · 2011 · 533 cites

Differential roles of NR2A and NR2B-containing NMDA receptors in cortical long-term potentiation and long-term depression.

The Journal of neuroscience : the official journal of the Society for Neuroscience · 2004 · 539 cites
Journals, researchers & institutions
Top journals
  • The Journal of neuroscience : the official journal of the Society for Neuroscience2
Leading researchers
  • Auberson YP1
  • Bashir ZI1
  • Brown MW1
  • Collingridge GL1
  • Jin M1
  • Johnson BE1
  • Koeglsperger T1
  • Li S1
Leading institutions
free-text, unnormalised
  • Center for Neurologic Diseases1
  • Medical Research Council Centre for Synaptic Plasticity1

Related drugs

2 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Aspartic Acid

Frequently co-studied with Ifenprodil in the research literature.

1 shared paper
Picrotoxin

Frequently co-studied with Ifenprodil in the research literature.

1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials